Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

ConditionsProstate Cancer After a Radical Treatment Biochemical Recurrence of Malignant Neoplasm of Prostate Biochemical Persistence of Prostate Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18+

SponsorHeinrich-Heine University, Duesseldorf

About this trial

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Eligibility criteria

Qualifiers

Informed Consent

Conduct of [18F]PSMA-1007 PET Imaging in the context of regular clinical care

Disqualifiers

Technical Flaws in the acquisition protocol

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Heinrich-Heine University, Duesseldorf

Lead sponsor

Source ClinicalTrials.gov